---
title: "Lu Pengqi, Deputy Director of the National Intellectual Property Administration, met with the Chairman of the Board of Roche Group from Switzerland"
description: "Lu Pengqi, Deputy Director of the China National Intellectual Property Administration, recently met with Christoph Franz, Chairman of the Board of Roche Group, emphasizing the importance of intellectu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/261886739.md"
published_at: "2025-10-20T12:37:40.000Z"
---

# Lu Pengqi, Deputy Director of the National Intellectual Property Administration, met with the Chairman of the Board of Roche Group from Switzerland

> Lu Pengqi, Deputy Director of the China National Intellectual Property Administration, recently met with Christoph Franz, Chairman of the Board of Roche Group, emphasizing the importance of intellectual property protection for the business environment and committing to equal protection for both domestic and foreign enterprises. Franz pointed out that intellectual property is the core competitiveness of innovative pharmaceutical companies, and Roche will increase its R&D investment in China to promote the globalization of local pharmaceutical innovation achievements

Recently, Lu Pengqi, Deputy Director of the China National Intellectual Property Administration, met with a visiting delegation led by Severin Schwan, Chairman of the Board of Roche Group, in Beijing. Lu Pengqi stated that in recent years, intellectual property protection has increasingly attracted the attention of both domestic and foreign enterprises as an important aspect of the business environment. The China National Intellectual Property Administration has always adhered to equal protection of intellectual property rights for both domestic and foreign-funded enterprises, effectively safeguarding the legitimate rights and interests of foreign investors. In the future, the China National Intellectual Property Administration will continue to maintain a proactive and open attitude, keeping good communication with rights holders and stakeholders from various countries. Schwan expressed that intellectual property is the core competitiveness for the survival and development of innovative pharmaceutical companies. Supported by China's continuously improving intellectual property protection system, more and more multinational pharmaceutical companies are confident in the Chinese market and are deepening their localization strategies. Roche Group will continue to expand its R&D investment in China and actively promote the benefits of pharmaceutical innovations originating from China to the world

### Related Stocks

- [RHHBY.US - Roche](https://longbridge.com/en/quote/RHHBY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Genentech Reports Positive Phase III Results For Gazyva In Primary Membranous Nephropathy | Genentech, part of the Roche Group, announced positive Phase III results for Gazyva in treating primary membranous nephr | [Link](https://longbridge.com/en/news/276037337.md) |
| Roche Appoints Mark Dawson As New Head Of Roche Pharma Research And Early Development | Roche Holding AG :ROCHE HOLDING AG - APPOINTMENT OF MARK DAWSON, M.D., PH.D., AS NEW HEAD OF ROCHE PHARMA RESEARCH AND E | [Link](https://longbridge.com/en/news/276097246.md) |
| Roche Announces Filing Acceptance Of New Drug Application For Giredestrant | Roche has announced that the FDA has accepted its New Drug Application for giredestrant, an investigational oral therapy | [Link](https://longbridge.com/en/news/276417142.md) |
| Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | Roche's Gazyva Meets Main Goal in Late-stage Kidney Disease Study | [Link](https://longbridge.com/en/news/276037536.md) |
| Roche Says Its Blood Cancer Drug Shows Positive Results in Trial | Roche announced that its blood cancer drug Gazyva/Gazyvaro has shown positive results in a late-stage trial for patients | [Link](https://longbridge.com/en/news/276037735.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.